Breakthrough EU approval for Dupixent offers new hope for children with eosinophilic esophagitis

Breakthrough EU approval for Dupixent offers new hope for children with eosinophilic esophagitis

The European Medicines Agency (EMA) has granted approval for Dupixent, a therapy developed by Sanofi and Regeneron, to treat eosinophilic esophagitis (EoE) in children as young as one year old. This decision marks a critical step in addressing a condition that has left young patients and their families with limited options. With this approval, Dupixent […]

Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis

Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis

French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission (EC) to market their Dupixent (dupilumab) injection in the European Union for eosinophilic esophagitis (EoE). Dupixent is indicated in adults and adolescents 12 years and over, who are not candidates for conventional medicinal treatment. With the approval, […]